NASDAQ:YARW Yarrow Bioscience (YARW) Stock Price, News & Analysis $26.07 -1.81 (-6.49%) Closing price 04:00 PM EasternExtended Trading$26.21 +0.14 (+0.54%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Yarrow Bioscience Stock (NASDAQ:YARW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Yarrow Bioscience alerts:Sign Up Key Stats Today's Range$25.73▼$27.9650-Day Range$25.50▼$42.9452-Week Range$15.77▼$46.95Volume183,898 shsAverage Volume133,044 shsMarket Capitalization$69.61 millionP/E RatioN/ADividend YieldN/APrice Target$58.00Consensus RatingHold Company Overview VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Read More Yarrow Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreYARW MarketRank™: Yarrow Bioscience scored higher than 40% of companies evaluated by MarketBeat, and ranked 505th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingYarrow Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialYarrow Bioscience has a consensus price target of $58.00, representing about 122.5% upside from its current price of $26.07.Amount of Analyst CoverageYarrow Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Yarrow Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Yarrow Bioscience is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Yarrow Bioscience is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioYarrow Bioscience has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.89% of the float of Yarrow Bioscience has been sold short.Short Interest Ratio / Days to CoverYarrow Bioscience has a short interest ratio ("days to cover") of 0.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Yarrow Bioscience has recently increased by 123.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldYarrow Bioscience does not currently pay a dividend.Dividend GrowthYarrow Bioscience does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Yarrow Bioscience this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Yarrow Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders3.03% of the stock of Yarrow Bioscience is held by insiders.Percentage Held by Institutions83.78% of the stock of Yarrow Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Yarrow Bioscience's insider trading history. Receive YARW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yarrow Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. YARW Stock News HeadlinesYarrow Bioscience Inc YARWSeptember 15, 2026 | morningstar.comMYarrow Bioscience Closes $172.5 Million Public OfferingSeptember 14, 2026 | finance.yahoo.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 24 at 1:00 AM | Paradigm Press (Ad)Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesSeptember 14, 2026 | finance.yahoo.comYarrow Bioscience Announces Underwritten Equity Offering AgreementSeptember 14, 2026 | tipranks.comYarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesSeptember 14, 2026 | businesswire.comYarrow Bioscience Stock Falls 7% On Pricing Of $150 Mln Public OfferingSeptember 13, 2026 | rttnews.comYarrow Bioscience prices $150M public offering of common stock at $26 per shareSeptember 11, 2026 | msn.comSee More Headlines YARW Stock Analysis - Frequently Asked Questions How have YARW shares performed this year? Yarrow Bioscience's stock was trading at $30.45 on July 29, 2026. Since then, YARW stock has decreased by 14.4% and is now trading at $26.07. How were Yarrow Bioscience's earnings last quarter? Yarrow Bioscience (NASDAQ:YARW) released its quarterly earnings data on Thursday, August, 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $3.33. The firm earned $0.10 million during the quarter, compared to analysts' expectations of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative trailing twelve-month return on equity of 84.40%. When did Yarrow Bioscience's stock split? Yarrow Bioscience's stock reverse split before market open on Monday, February 13th 2023.The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Yarrow Bioscience's major shareholders? Yarrow Bioscience's top institutional investors include ADAR1 Capital Management LLC (440.30%), Nantahala Capital Management LLC (298.51%), Braidwell LP (136.73%) and Susquehanna International Group LLP (17.75%). View institutional ownership trends. How do I buy shares of Yarrow Bioscience? Shares of YARW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Yarrow Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Yarrow Bioscience investors own include NIO (NIO), Tesla (TSLA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA). Company Calendar Record date for 7/23 Dividend7/22/2026Dividend Payable7/23/2026Last Earnings8/13/2026Today9/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 7 days, YARW's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:YARW Previous SymbolNASDAQ:VYNE CIK1566044 Webwww.yarrowbioscience.com Phone(203) 433-7577FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Yarrow Bioscience$58.00 High Price Target$58.00 Low Price Target$58.00 Potential Upside/Downside+122.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.48 million Net Margins-4,726.21% Pretax Margin-4,900.26% Return on Equity-84.40% Return on Assets-77.68% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$570 thousand Price / Sales122.12 Cash FlowN/A Price / Cash FlowN/A Book Value$41.71 per share Price / Book0.63Miscellaneous Outstanding Shares2,670,000Free Float2,589,000Market Cap$69.61 million OptionableN/A Beta2.01 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:YARW) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yarrow Bioscience Please log in to your account or sign up in order to add this asset to your watchlist. Share Yarrow Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
